Polyamide-Prostate Agent Combination for Resistant Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as androgen deprivation therapy and enzalutamide, often lead to castration-resistant forms that are resistant to available therapies, necessitating the development of new therapeutics effective against treatment-resistant prostate cancers.
Innovation Solution
A combination drug comprising a polyamide that modulates androgen receptor (AR) and glucocorticoid receptor (GR)-mediated gene regulation by binding to specific DNA sequences, combined with prostate agents like hormone therapeutics, anti-androgens, or taxanes, to inhibit AR nuclear translocation and signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If androgen deprivation therapy (ADT) is used to treat prostate cancer, then androgen receptor signaling is inhibited, but castration-resistant forms emerge that are resistant to available therapies
Solution Approach 1:
The patent divides the therapeutic approach into two distinct components: a polyamide compound that binds to specific DNA sequences (ARE/GRE) and a prostate agent that targets the androgen receptor. This segmentation allows each component to address different mechanisms of resistance independently, preventing the development of comprehensive resistance that occurs with single-agent therapy.
Solution Approach 2:
The patent employs a composite therapeutic strategy by combining a polyamide compound with a prostate agent into a combination drug. This composite approach targets multiple pathways simultaneously - the polyamide component binds to DNA response elements to block gene transcription, while the prostate agent directly inhibits androgen receptor signaling, creating a multi-pronged attack that overcomes resistance mechanisms.
2Reliability
If enzalutamide is used to inhibit androgen-AR binding, then AR nuclear translocation is prevented, but patients develop resistance to drugs like enzalutamide
Solution Approach 1:
The polyamide compound acts as an intermediary mechanism that operates upstream of the androgen receptor. By binding to androgen response elements in DNA, the polyamide blocks gene transcription independently of whether the androgen receptor is present or active. This intermediary approach bypasses resistance mechanisms that develop against direct AR-targeting agents like enzalutamide.
Solution Approach 2:
Instead of directly blocking the androgen receptor (the conventional approach), the patent inverts the strategy by targeting the DNA response elements that the receptor binds to. This reverse approach - blocking the destination rather than the vehicle - allows therapeutic effect even when the androgen receptor remains functional or overexpressed, as is the case in enzalutamide-resistant cancers.
3Reliability
If combination drugs comprising polyamide and prostate agent are used, then AR and GR signaling are inhibited, but device complexity increases
Solution Approach 1:
The patent merges two therapeutic agents with complementary mechanisms of action into a single combination drug formulation. The polyamide compound and prostate agent are administered together to simultaneously target DNA response elements and the androgen receptor, achieving enhanced therapeutic effectiveness through synergistic action while managing the complexity through coordinated formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination drug effectively reduces prostate cancer cell growth and tumor volume, even in enzalutamide-resistant cases, by potently inhibiting AR and GR signaling, and can be administered to achieve significant therapeutic effects with minimal toxicity.
Implementation Method 1
Polyamides of the current invention, in certain embodiments, are capable of entering a cell and of binding to the androgen response element (ARE) and/or the glucocorticoid response element (GRE) in the genome of the cell so as to inhibit binding of nuclear hormone receptors (NHR) to the ARE and/or GRE
Data Source
AI summary
The present invention relates to compositions and methods for the treatment of prostate cancer. The present invention relates to polyamides and prostate agents, for example, to inhibit an androgen receptor signaling axis, and the use of these compositions in the treatment of prostate cancer.